Mobile

Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 µg/kg) plus G-CSF (10 µg/kg) Versus G-CSF (10 µg/kg) plus Plac...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005320-16

Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 µg/kg) plus G-CSF (10 µg/kg) Versus G-CSF (10 µg/kg) plus Placebo to Mobilize and Collect ≥ 6×106 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objective of this long-term observational study is to assess progression-free survival and overall survival of patients treated with at least 1 dose of study treatment (placebo or plerixafor) for a period of 5 years following the first dose of study treatment (placebo or plerixafor) in protocol AMD3100-3102.

Critère d'inclusion

  • Survival of multiple myeloma patients following autologous transplant in study AMD3100-3102

Liens